Open an account

Panacos Pharmaceuticals

PANC · OTC

$0.00+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About PANC

Panacos Pharmaceuticals, Inc. engages in the discovery and development of small-molecule oral drug which is designed to treat human immunodeficiency virus and other major human viral diseases. The company is headquartered in Watertown, Massachusetts and currently employs 41 full-time employees. The firm's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The firm has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.

Employees
41
Headquarters
Watertown, Massachusetts
Listed
Jun 11, 1998
Sector
Health Care
Industry
Biotechnology

PANC key statistics

Market cap
54
Price-earnings ratio
-0.00
Dividend yield
—
Average volume
110
Volume
10
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.00
52 Week low
$0.00

Panacos Pharmaceuticals (PANC) at a glance

As of Feb 24, 2026, Panacos Pharmaceuticals (PANC) shares are priced at $0.00, giving the company a market cap of 54 and a price-to-earnings ratio of 0.00.

Volume so far is 10 shares, below the average of 110 shares a day.

Panacos Pharmaceuticals met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q3 FY08 it reported -$0.15 per share against an estimate of -$0.1989.

PANC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 14.8% on average.

  1. Q4 FY06: reported -$0.17 per share against an estimate of -$0.204
  2. Q1 FY07: reported -$0.19 per share against an estimate of -$0.2179
  3. Q2 FY07: reported -$0.19 per share against an estimate of -$0.1812
  4. Q3 FY07: reported -$0.15 per share against an estimate of -$0.1777
  5. Q4 FY07: reported -$0.17 per share against an estimate of -$0.2017
  6. Q1 FY08: reported -$0.16 per share against an estimate of -$0.1904
  7. Q2 FY08: reported -$0.18 per share against an estimate of -$0.1836
  8. Q3 FY08: reported -$0.15 per share against an estimate of -$0.1989

Similar companies

Companies in the same industry as Panacos Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.